No Data
No Data
Harbin Pharmaceutical Group (SHSE:600664) Strong Profits May Be Masking Some Underlying Issues
Report for the third quarter of 2024 of Harbin Pharmaceutical Group Co., Ltd.
Harbin Pharmaceutical Group (600664.SH): net income of 0.508 billion yuan in the first three quarters, a year-on-year increase of 74.97%.
On October 25th, Pharmaron Group (600664.SH) released its third quarter report, with revenue for the first three quarters reaching 12.256 billion yuan, a year-on-year increase of 6.63%. Net income was 0.508 billion yuan, up 74.97% year-on-year, non-GAAP net income was 0.47 billion yuan, up 91.39% year-on-year, and basic earnings per share was 0.20 yuan.
Harbin Pharmaceutical Group (600664.SH) released its performance for the first three quarters, with a net income of 0.508 billion yuan, a year-on-year increase of 74.97%.
harbin pharmaceutical group (600664.SH) released the report for the first three quarters of 2024, during the reporting period the company achieved revenue...
These 4 Measures Indicate That Harbin Pharmaceutical Group (SHSE:600664) Is Using Debt Safely
Shareholders in Harbin Pharmaceutical Group (SHSE:600664) Have Lost 26%, as Stock Drops 5.0% This Past Week
Investors Don't See Light At End Of Harbin Pharmaceutical Group Co., Ltd.'s (SHSE:600664) Tunnel And Push Stock Down 26%No Data
No Data
